- The FDA approves Cerus' (NASDAQ:CERS) Intercept Blood System for cryoprecipitation, specifically for producing pathogen-reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
- Fibrinogen is a protein that plays an essential role in blood clotting.
- The FDA OK'd the pathogen-reducing device in 2014 for plasma and single donor apheresis platelets.
- https://seekingalpha.com/news/3639931-fda-oks-new-use-of-cerus-intercept-system-shares-up-7
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.